Skip to content Skip to footer
Subscribe Now
INSIGHTS+

Disease of the Month – Fabry Disease

Shots:  Fabry disease is a rare inherited neurological disorder that affects the body's ability to break down lipids into smaller components  In this reprise of our Disease of the Month report, we bring an illuminating account of Fabry Disease with deep dive analysis of epidemiology, market size, disease management, available therapies, patient advocacy groups, and…
June 12, 2024

Read more

VIEWPOINTS_Patrick Mooney_2024
VIEWPOINTS

Intraocular Drug Delivery: Patrick Mooney from SpyGlass Pharma in Conversation with PharmaShots

Shots:  Out of the 5M cataract procedures in the US, around one-fifth are conducted on patients with glaucoma or ocular hypertension. There’s an unmet need for drug delivery for patients who struggle with topical drops  Today, with PharmaShots, CEO of SpyGlass Pharma, Patrick Mooney, sharing insights from the data presented at the ASCRS Annual Meeting  Patrick…
June 10, 2024

Read more

Insights+ Key Biosimilars Events of May 2024
INSIGHTS+

Insights+ Key Biosimilars Events of May 2024

Shots:    Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency     Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients     During May, Teva & Alvotech launched Simlandi injection Treat Multiple Indications. Our…
June 4, 2024

Read more

VIEWPOINTS_Donna Carstens_2024
VIEWPOINTS

SEA Management: Donna Carstens from AstraZeneca in a Riveting Conversation with PharmaShots

Shots:  Recently AstraZeneca’s FASENRA (benralizumab) received approval from the US FDA as an add-on maintenance treatment for patients (≥ 6 yrs.) with severe asthma and with an eosinophilic phenotype  Today, at PharmaShots we have with us Donna Carstens, Senior Medical Director Respiratory, Fasenra at AstraZeneca  Donna shares insights from the TATE study an open-label, multinational,…
June 3, 2024

Read more

VIEWPOINTS_Kurt Harrington_2024
VIEWPOINTS

Alternative Treatment: Kurt Harrington from Ventoux Biosciences in a Gripping Conversation with PharmaShots

Shots:  Dupuytren’s disease is a chronic progressive & debilitating fibrosis that impacts hands. There’s an unmet need to treat Dupuytren’s disease, especially when looking for a pharmacological substitute for surgical interventions  Today, at PharmaShots, we had the pleasure to speak with Kurt Harrington, CEO and Founder of Ventoux Biosciences  Kurt shares insights from the preclinical…
May 29, 2024

Read more

Diagnostic Top 20 2024
TOP 20

Top 20 Diagnostic Companies of 2024 

Shots:   Propelled by unceasing innovations and inch-perfect precision, the diagnostic industry is advancing at an astonishing pace  In 2023, the global diagnostic test market size was valued at $210.58B and is envisioned to reach $284.38B by 2033, registering a CAGR of 3.05 percent from 2024 to 2033. Roche reclaims its first position with a revenue…
May 23, 2024

Read more

Disease of the Month – Sjögren’s Syndrome
INSIGHTS+

Disease of the Month – Sjögren’s Syndrome

Shots:  A rare autoimmune condition, Sjögren’s Syndrome is characterized by dry mouth and eye. The condition affects 0.5 to 1% of the global population of which 90% of patients are women  In this reprise of our Disease of the Month report, we bring an illuminating account of Sjögren’s Syndrome with deep dive analysis of epidemiology, market size, disease management, available therapies, patient…
May 16, 2024

Read more

PharmaShots Magazine - May 2024 Edition
MAGAZINE

PharmaShots Magazine – May 2024 Edition

Throughout April PharmaShots was swamped with the heavy traffic of life science updates. As an official media partner to Reuters Events, PharmaShots was present in Barcelona, covering groundbreaking presentations from leading biopharma companies.  Our most-read top 20 section featured reports on Top 20 RNAi Therapeutic Companies, Top 20 Biopharma Deal Terminations of 2023, and Top 20 Biopharma Companies. For…
May 15, 2024

Read more

Load more